| 107.16 -2.46 (-2.24%) | 04-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 135.05 | 1-year : | 157.73 |
| Resists | First : | 115.62 | Second : | 135.05 |
| Pivot price | 104.01  |
|||
| Supports | First : | 103.34 | Second : | 95.75 |
| MAs | MA(5) : | 110.58 |
MA(20) : | 103.27 |
| MA(100) : | 149.57 |
MA(250) : | 155.49 |
|
| MACD | MACD : | -1.9 |
Signal : | -4.4 |
| %K %D | K(14,3) : | 73.1 |
D(3) : | 83.6 |
| RSI | RSI(14): 47.5 |
|||
| 52-week | High : | 211 | Low : | 66.56 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ICLR ] has closed below upper band by 35.3%. Bollinger Bands are 44.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 113.76 - 114.33 | 114.33 - 114.7 |
| Low: | 106.81 - 107.55 | 107.55 - 108.03 |
| Close: | 108.55 - 109.68 | 109.68 - 110.4 |
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Tue, 31 Mar 2026
Icon Plc $ICLR Shares Bought by Allspring Global Investments Holdings LLC - marketbeat.com
Sun, 29 Mar 2026
ICON Stock Trades At Deep Discount Amid Probe - Let's Data Science
Sun, 29 Mar 2026
Is ICON Public Limited Company (ICLR) A Good Stock To Buy Now? - Yahoo Finance
Thu, 26 Mar 2026
ICON stock raised to Outperform at BMO (ICLR:NASDAQ) - seekingalpha.com
Tue, 24 Mar 2026
ICON-Advarra deal aims to cut trial friction and widen access - Stock Titan
Tue, 17 Feb 2026
Did You Suffer Losses in ICON Public Limited Company (ICLR)? Contact Levi & Korsinsky About Securities Fraud Claims - TMX Newsfile
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 76 (M) |
| Shares Float | 76 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 109.8 (%) |
| Shares Short | 2,030 (K) |
| Shares Short P.Month | 2,000 (K) |
| EPS | 7.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 122.25 |
| Profit Margin | 7.4 % |
| Operating Margin | 12.6 % |
| Return on Assets (ttm) | 4.1 % |
| Return on Equity (ttm) | 6.2 % |
| Qtrly Rev. Growth | 0.6 % |
| Gross Profit (p.s.) | 29.85 |
| Sales Per Share | 106.07 |
| EBITDA (p.s.) | 19.9 |
| Qtrly Earnings Growth | -98.7 % |
| Operating Cash Flow | 1,140 (M) |
| Levered Free Cash Flow | 925 (M) |
| PE Ratio | 14.42 |
| PEG Ratio | 0 |
| Price to Book value | 0.87 |
| Price to Sales | 1 |
| Price to Cash Flow | 7.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|